ESSA Pharma Company Profile (TSE:EPI)

About ESSA Pharma (TSE:EPI)

ESSA Pharma logoESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: C$10.04 million
  • Outstanding Shares: 29,101,000
Average Prices:
  • 50 Day Moving Avg: C$0.36
  • 200 Day Moving Avg: C$0.36
  • 52 Week Range: C$0.31 - C$4.60
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: C($0.08) per share
  • Price / Book: -4.60
Profitability:
  • EBITDA: ($13,730,000.00)
  • Return on Assets: 130.13%
Misc:
  • Average Volume: 80,941 shs.
  • Short Ratio: 0.04
 

Frequently Asked Questions for ESSA Pharma (TSE:EPI)

What is ESSA Pharma's stock symbol?

ESSA Pharma trades on the Tornton Stock Exchange (TSX) under the ticker symbol "EPI."

When will ESSA Pharma make its next earnings announcement?

ESSA Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, December, 13th 2017. View Earnings Estimates for ESSA Pharma.

Who are some of ESSA Pharma's key competitors?

Who are ESSA Pharma's key executives?

ESSA Pharma's management team includes the folowing people:

  • Richard M. Glickman LL.D., Chairman of the Board
  • David Ross Parkinson M.D., President, Chief Executive Officer, Director
  • David Wood, Chief Financial Officer
  • Peter Virsik, Chief Operating Officer, Executive Vice President
  • Raymond L. Andersen, Chief Technology Officer, Director
  • Marianne D. Sadar, Chief Scientific Officer, Director
  • Frank Perabo, Chief Medical Officer
  • Franklin M. Berger, Director
  • Scott Requadt J.D., Director
  • Gary Sollis, Director

How do I buy ESSA Pharma stock?

Shares of ESSA Pharma and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is ESSA Pharma's stock price today?

One share of ESSA Pharma stock can currently be purchased for approximately C$0.35.


MarketBeat Community Rating for ESSA Pharma (TSE EPI)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  67
MarketBeat's community ratings are surveys of what our community members think about ESSA Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ESSA Pharma (TSE:EPI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: N/A
Consensus Price Target History for ESSA Pharma (TSE:EPI)
Price Target History for ESSA Pharma (TSE:EPI)
Analysts' Ratings History for ESSA Pharma (TSE:EPI)
Show:
DateFirmActionRatingPrice TargetDetails
9/12/2017Bloom BurtonDowngradeBuy -> HoldView Rating Details
8/2/2017Dawson JamesReiterated RatingBuyView Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for ESSA Pharma (TSE:EPI)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for ESSA Pharma (TSE:EPI)
Current Year EPS Consensus Estimate: $-0.350 EPS

Dividends

Dividend History for ESSA Pharma (TSE:EPI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ESSA Pharma (TSE:EPI)
Insider Trades by Quarter for ESSA Pharma (TSE:EPI)
Insider Trades by Quarter for ESSA Pharma (TSE:EPI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/24/2015Robert RiederDirectorBuy3,600C$9.00C$32,389.20
8/31/2015Marianne SadarDirectorSell22,000C$7.60C$167,200.00
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ESSA Pharma (TSE:EPI)
Latest Headlines for ESSA Pharma (TSE:EPI)
Source:
DateHeadline
americanbankingnews.com logoBloom Burton Downgrades ESSA Pharma Inc (EPI) to Hold
www.americanbankingnews.com - September 13 at 7:18 PM
prnewswire.com logoESSA Pharma Announces Results from the Phase 1 Clinical Trial of EPI-506 for Treatment of mCRPC and Updates ... - PR Newswire (press release)
www.prnewswire.com - September 13 at 12:15 AM
finance.yahoo.com logoESSA Pharma Provides Business Update and Announces Financial Results for the Fiscal Third Quarter Ended June 30, 2017
finance.yahoo.com - August 14 at 11:42 PM
americanbankingnews.com logoESSA Pharma Inc (EPI) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 9 at 7:02 AM
americanbankingnews.com logoESSA Pharma Inc (EPI) Given "Buy" Rating at Dawson James
www.americanbankingnews.com - August 8 at 7:00 AM
reuters.com logoBRIEF-Essa Pharma provides further update on proposed equity offering
www.reuters.com - July 24 at 10:01 AM
finance.yahoo.com logoESSA Pharma Provides Further Update on Proposed Equity Offering
finance.yahoo.com - July 24 at 10:01 AM
finance.yahoo.com logoESSA Pharma Announces Receipt of NASDAQ Notice of Market Value Deficiency
finance.yahoo.com - July 21 at 8:15 PM
finance.yahoo.com logoESSA Pharma Announces Receipt of NASDAQ Notice of Bid Price Deficiency
finance.yahoo.com - July 20 at 3:51 PM
prnewswire.com logoESSA Pharma Announces Overnight Marketed Equity Offering - PR Newswire (press release)
www.prnewswire.com - July 13 at 7:38 PM
prnewswire.com logoESSA Pharma Announces Pricing of Proposed Equity Offering - PR Newswire (press release)
www.prnewswire.com - July 13 at 7:38 PM
finance.yahoo.com logoIIROC Trade Resumption - ESSA Pharma Inc.
finance.yahoo.com - July 13 at 7:38 PM
finance.yahoo.com logoIIROC Trade Resumption - EPI
finance.yahoo.com - July 13 at 7:38 PM
finance.yahoo.com logoIIROC Trading Halt - EPI
finance.yahoo.com - July 12 at 6:58 PM
seekingalpha.com logoESSA Pharma continues slide; shares down 36% - Seeking Alpha
seekingalpha.com - June 6 at 5:26 PM
prnewswire.com logoESSA Pharma Presents Data From Phase 1 Trial of EPI-506 at 2017 ASCO Annual Meeting - PR Newswire (press release)
www.prnewswire.com - June 6 at 5:26 PM
streetinsider.com logoESSA Pharma (EPIX) Says Data from Phase 1 Trial of EPI-506 to be Presented at ASCO - StreetInsider.com
www.streetinsider.com - May 19 at 8:01 AM
streetinsider.com logoForm 6-K ESSA Pharma Inc. For: Apr 03 - StreetInsider.com
www.streetinsider.com - April 3 at 2:18 PM
prnewswire.com logoESSA Pharma Provides Business Update and Announces Financial Results for the First Quarter Ended December 31 ... - PR Newswire (press release)
www.prnewswire.com - February 13 at 10:58 PM
feeds.benzinga.com logo10 Biggest Mid-Day Losers For Wednesday
feeds.benzinga.com - December 28 at 1:27 PM

Social

Chart

ESSA Pharma (EPI) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.